GSK650394 Suppresses SGK1-HDAC4-HMGB1 Signaling to Alleviate Diabetic Neuropathic Pain
Copy code to add this image to your page
Diabetic neuropathic pain presents a distinct clinical challenge driven by persistent metabolic distress and neuroinflammatory cascades within the peripheral and central nervous systems. Central sensitization in the spinal dorsal horn plays a key role in maintaining thermal hyperalgesia and mechanical allodynia during chronic hyperglycemia. Among the serine/threonine protein kinases, serum- and glucocorticoid-inducible kinase 1 (SGK1) operates as an early responder to cellular metabolic stress, osmotic fluctuations, and inflammatory cytokines. In rat models of type 2 diabetic neuropathy, sustained metabolic disruption elevates SGK1 activity within spinal dorsal horn neurons. This enzymatic hyperactivation initiates downstream epigenetic and transcriptional shifts that sustain persistent pain hypersensitivity.
The biological cascade regulated by SGK1 centers on its downstream substrate, histone deacetylase 4 (HDAC4). Under basal conditions, unphosphorylated HDAC4 resides predominantly inside the neuronal nucleus. In this nuclear compartment, HDAC4 acts as a transcriptional repressor by associating with chromatin complexes and suppressing the promoter region of high-mobility group box 1 (HMGB1). When SGK1 undergoes activating phosphorylation at its catalytic domain, it directly phosphorylates HDAC4 at specific serine residues. Phosphorylation of HDAC4 alters its structural conformation and exposes a nuclear export signal. This conformational change facilitates export from the nucleus into the cytoplasm via 14-3-3 chaperone protein interactions.
Cytoplasmic accumulation of HDAC4 prevents its binding to the HMGB1 promoter. Consequently, nuclear chromatin shifts into an open transcriptional state, relieving repression and prompting the transcription of HMGB1. HMGB1 functions as a potent damage-associated molecular pattern mediator. Following upregulation, neuronal HMGB1 translocates to the extracellular space, where it interacts with toll-like receptor 4 and advanced glycation end-product receptors on microglial and astrocytic membranes. This ligand-receptor engagement recruits myddosome complexes, triggering nuclear factor kappa B nuclear translocation and inducing neuroinflammatory cytokine release. These signaling events lower the activation threshold of dorsal horn nociceptive neurons.
Targeting this biochemical cascade through small-molecule inhibition offers a strategy to dissect and interrupt spinal pain facilitation. Small-molecule inhibitor GSK650394 exhibits high selectivity for SGK1 over closely related AGC family kinases, such as protein kinase B and protein kinase A. Administration of GSK650394 effectively blocks ATP-binding pocket interactions within the kinase domain of SGK1. In experimental rat models of type 2 diabetic neuropathic pain, intrathecal delivery of GSK650394 inhibits SGK1 autophosphorylation and substrate phosphorylation in spinal tissue homogenates. This target engagement directly impacts HDAC4 nucleocytoplasmic distribution.
Following treatment with GSK650394, HDAC4 phosphorylation levels drop significantly within dorsal horn neurons. Unphosphorylated HDAC4 remains localized inside the nuclear compartment, re-establishing transcriptional suppression of HMGB1. Biochemical assays confirm a corresponding reduction in cytosolic HMGB1 protein concentrations and a decrease in downstream inflammatory markers. At the organismal level, intrathecal administration of GSK650394 reverses behavioral manifestations of neuropathic pain in diabetic animals. Evaluated across established time points, treated rodents show marked recovery in thermal withdrawal latency and mechanical withdrawal thresholds compared to vehicle controls.
These empirical findings establish that the spinal SGK1-HDAC4-HMGB1 signaling sequence functions as an active driver of dorsal horn neuroinflammation and nociceptive sensitization. Interrupting this cascade via target-specific inhibition demonstrates that epigenetic dysregulation in diabetic neuropathy remains reversible under defined experimental conditions. Consequently, SGK1 represents an actionable node for modulating nuclear-cytoplasmic protein trafficking and downstream inflammatory gene expression in central pain processing networks.
Pharmacological Modulation of the Spinal SGK1 Signalling Axis
Copy code to add this image to your page
GSK650394 functions as a selective inhibitor of serum- and glucocorticoid-inducible kinase 1 (SGK1). In diabetic neuropathic pain models, SGK1 hyperactivation induces phosphorylation and cytosolic translocation of histone deacetylase 4 (HDAC4). Cytoplasmic HDAC4 retention relieves nuclear transcriptional repression of high-mobility group box 1 (HMGB1), promoting neuroinflammation and pain hypersensitivity. Inhibiting SGK1 with GSK650394 prevents HDAC4 phosphorylation, restores nuclear HDAC4 repression of HMGB1, and reduces thermal hyperalgesia and mechanical allodynia in spinal neurons.
SGK1 Activation Drives Cytosolic HDAC4 Accumulation in Spinal Neurons
Metabolic stress elevates spinal SGK1 activity. Activated SGK1 targets nuclear HDAC4, catalyzing serine residue phosphorylation and altering protein confirmation. This modification promotes binding to cytosolic 14-3-3 chaperone proteins. Consequently, HDAC4 leaves the nucleus. Nuclear depletion of HDAC4 eliminates its baseline transcriptional repression of HMGB1, causing chromatin remodeling at the promoter site. The resulting derepression increases HMGB1 expression within dorsal horn neurons. Extracellular HMGB1 release subsequently activates local glial networks, amplifying nociceptive signal transmission across central sensory pathways.
Intrathecal GSK650394 Attenuates HMGB1 Upregulation and Thermal Allodynia
Direct lumbar administration of GSK650394 blocks SGK1 catalytic function within the spinal dorsal horn. HDAC4 phosphorylation dropped sharply. Pharmacological blockade prevents nucleocytoplasmic export, maintaining nuclear HDAC4 occupancy at the HMGB1 promoter region. As a result, cellular HMGB1 expression returns to baseline concentrations. Rats receiving intrathecal GSK650394 show marked improvements in mechanical withdrawal thresholds and thermal withdrawal latencies. Central pain sensitization subsided under these controlled experimental conditions.